<ul><li>Hoth Therapeutics, Inc. collaborates with Washington University School of Medicine to advance Alzheimer's disease research.</li><li>The partnership focuses on studying HT-ALZ, an FDA-approved NK-1 receptor antagonist, to reduce neuroinflammation and improve cognitive function in Alzheimer's disease.</li><li>In preclinical studies, chronic administration of HT-ALZ demonstrated significant improvement in cognitive functions in mice models of Alzheimer's.</li><li>Hoth Therapeutics, Inc. hopes that HT-ALZ can be a promising therapeutic intervention for Alzheimer's disease.</li></ul>

Hoth Flat on Hookup with Washington Univ.

Discover more